IL167319A - Trans 4 - (4,3 - dichlorophenyl) - 1, 2, 3, 4– tetrahydro - 1 - Naphthalamine for use in the treatment of central nervous system disorders - Google Patents

Trans 4 - (4,3 - dichlorophenyl) - 1, 2, 3, 4– tetrahydro - 1 - Naphthalamine for use in the treatment of central nervous system disorders

Info

Publication number
IL167319A
IL167319A IL167319A IL16731905A IL167319A IL 167319 A IL167319 A IL 167319A IL 167319 A IL167319 A IL 167319A IL 16731905 A IL16731905 A IL 16731905A IL 167319 A IL167319 A IL 167319A
Authority
IL
Israel
Prior art keywords
compound
dichlorophenyl
tetrahydronaphthalen
disorder
formamide
Prior art date
Application number
IL167319A
Other languages
English (en)
Hebrew (he)
Inventor
Thomas P Jerussi
Kevin Qun Fang
Mark Currie
Original Assignee
Sunovion Pharmaceuticals Inc
Thomas P Jerussi
Kevin Qun Fang
Mark Currie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunovion Pharmaceuticals Inc, Thomas P Jerussi, Kevin Qun Fang, Mark Currie filed Critical Sunovion Pharmaceuticals Inc
Publication of IL167319A publication Critical patent/IL167319A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
    • C07C2602/28—Hydrogenated naphthalenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL167319A 2002-09-16 2005-03-08 Trans 4 - (4,3 - dichlorophenyl) - 1, 2, 3, 4– tetrahydro - 1 - Naphthalamine for use in the treatment of central nervous system disorders IL167319A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41130502P 2002-09-16 2002-09-16
US41130402P 2002-09-16 2002-09-16
PCT/US2003/029110 WO2004024669A1 (en) 2002-09-16 2003-09-16 Treatment of cns disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide

Publications (1)

Publication Number Publication Date
IL167319A true IL167319A (en) 2013-10-31

Family

ID=31998027

Family Applications (1)

Application Number Title Priority Date Filing Date
IL167319A IL167319A (en) 2002-09-16 2005-03-08 Trans 4 - (4,3 - dichlorophenyl) - 1, 2, 3, 4– tetrahydro - 1 - Naphthalamine for use in the treatment of central nervous system disorders

Country Status (15)

Country Link
US (6) US7087785B2 (https=)
EP (1) EP1542961B1 (https=)
JP (1) JP4610336B2 (https=)
KR (2) KR101067045B1 (https=)
CN (1) CN101712626B (https=)
AU (1) AU2003272460B2 (https=)
BR (1) BRPI0314377B8 (https=)
CA (1) CA2498152C (https=)
DK (1) DK1542961T3 (https=)
ES (1) ES2431519T3 (https=)
IL (1) IL167319A (https=)
MX (1) MXPA05002700A (https=)
NZ (1) NZ538741A (https=)
PT (1) PT1542961E (https=)
WO (1) WO2004024669A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0314377B8 (pt) * 2002-09-16 2021-05-25 Sepracor Inc composto, composição farmacêutica, tablete ou cápsula, uso de uma quantidade terapeuticamente eficaz, e, processo para preparar um composto
US8134029B2 (en) 2002-09-16 2012-03-13 Sunovion Pharmaceuticals Inc. Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine
US20050176680A1 (en) * 2003-12-11 2005-08-11 Sepracor, Inc. Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
JP2007517056A (ja) * 2003-12-29 2007-06-28 セプラコア インコーポレーテッド ピロール及びピラゾールｄａａｏ阻害剤
US20060199739A1 (en) * 2005-03-02 2006-09-07 Olav Messerschmidt Limonene-containing herbicide compositions, herbicide concentrate formulations and methods for making and using same
EP2455075B1 (en) * 2005-07-06 2018-06-20 Sunovion Pharmaceuticals Inc. Process for Preparation of trans 4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine
JP2009522721A (ja) * 2005-12-29 2009-06-11 ユーティーシー パワー コーポレイション ガス輸送式燃料電池冷媒の循環
NZ569608A (en) * 2006-01-06 2011-09-30 Sepracor Inc Tetralone-based monoamine reuptake inhibitors
US20070203111A1 (en) 2006-01-06 2007-08-30 Sepracor Inc. Cycloalkylamines as monoamine reuptake inhibitors
CN101421228B (zh) * 2006-03-31 2014-05-21 塞普拉柯公司 手性酰胺和胺的制备
AU2013211500B2 (en) * 2006-03-31 2016-08-04 Sepracor Inc Preparation of chiral amides and amines
EP2043745A2 (en) * 2006-05-31 2009-04-08 SEPRACOR Inc Treatment of pain disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine and its formamide
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
US7884124B2 (en) * 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
BRPI0717171B1 (pt) * 2006-09-25 2023-10-17 Archer Daniels Midland Company Material superabsorvente
US20080082066A1 (en) * 2006-10-02 2008-04-03 Weyerhaeuser Co. Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks
US8138377B2 (en) * 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
FR2909376A1 (fr) * 2006-11-30 2008-06-06 Cerep Sa Procedes de preparation de la desmethulsertraline ou d'un de ses sels pharmaceutiquement acceptables
CA2676432A1 (en) * 2007-01-18 2008-07-24 Sepracor, Inc. Inhibitors of d-amino acid oxidase
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
CA2688493C (en) 2007-05-31 2016-04-19 Sepracor Inc. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
US20100120740A1 (en) * 2008-08-07 2010-05-13 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
CN102573823B (zh) * 2009-05-13 2015-01-07 桑诺维恩药品公司 包含反式去甲舍曲林和血清素受体1a激动剂/拮抗剂的组合物及其用途
US20110034434A1 (en) * 2009-08-07 2011-02-10 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
WO2011069032A2 (en) * 2009-12-04 2011-06-09 Sunovion Pharmaceuticals Inc. Formulations, salts and polymorphs of transnorsertraline and uses thereof
US10085414B2 (en) 2011-05-19 2018-10-02 Gilrose Pharmaceuticals, Llc Pre-frontal cortex processing disorder speech, gait and limb impairments treatment
US9220712B2 (en) 2011-05-19 2015-12-29 Gilrose Pharmaceuticals, Llc Pharmaceutical intervention and method for treating an apraxia of speech in children
US9682073B2 (en) 2011-05-19 2017-06-20 Gilrose Pharmaceuticals, Llc Pre-frontal cortex processing disorder gait and limb impairments treatment
US20140163070A1 (en) 2012-05-17 2014-06-12 Bruce Roseman Treatment for cerebral palsy impaired speech in children
WO2012158892A2 (en) 2011-05-19 2012-11-22 Bruce Roseman A method of treating apraxia of speech in children
US8883815B2 (en) 2011-05-19 2014-11-11 Gilrose Pharmaceuticals, Llc Treatment for cerebral palsy impaired speech in children
AU2015259337A1 (en) * 2014-05-13 2016-12-08 Sunovion Pharmaceuticals Inc. Methods and compositions of dasotraline for treatment of ADHD
JP2017515849A (ja) * 2014-05-13 2017-06-15 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． Ａｄｈｄを治療するためのダソトラリン用量および治療方法
WO2016046669A2 (en) * 2014-09-27 2016-03-31 Mohan M Alapati Compositions and methods for the treatment of depression and neurological diseases
US20200405867A1 (en) 2018-01-19 2020-12-31 Sunovion Pharmaceuticals Inc. Oral dosage forms
WO2020092496A1 (en) 2018-10-31 2020-05-07 Sunovion Pharmaceuticals Inc. Methods of treating central nervous system disorders
EP3800178A1 (en) 2019-10-01 2021-04-07 Moehs Ibérica, S.L. Preparation of enamide intermediate for the synthesis of dasotraline

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59497B2 (ja) * 1979-11-01 1984-01-07 フアイザ−・インコ−ポレ−テツド トランス−４−フエニル−１，２，３，４−テトラヒドロ−１−ナフタレンアミンの抗抑うつ性誘導体
US4556676A (en) * 1979-11-01 1985-12-03 Pfizer Inc. Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4981870A (en) * 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
US5554383A (en) 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
US5778986A (en) * 1997-08-05 1998-07-14 Davis; Floyd A. Device to remove divots
US6245782B1 (en) 1999-05-17 2001-06-12 Heartdrug Research L.L.C. Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
BRPI0314377B8 (pt) * 2002-09-16 2021-05-25 Sepracor Inc composto, composição farmacêutica, tablete ou cápsula, uso de uma quantidade terapeuticamente eficaz, e, processo para preparar um composto

Also Published As

Publication number Publication date
HK1143559A1 (en) 2011-01-07
US7790772B2 (en) 2010-09-07
AU2003272460A2 (en) 2004-04-30
US20040092605A1 (en) 2004-05-13
US7087785B2 (en) 2006-08-08
US20060014982A1 (en) 2006-01-19
US7423179B2 (en) 2008-09-09
CN101712626A (zh) 2010-05-26
CN101712626B (zh) 2013-11-20
AU2003272460B2 (en) 2009-12-17
US20080280993A1 (en) 2008-11-13
WO2004024669A1 (en) 2004-03-25
US7589237B2 (en) 2009-09-15
CA2498152A1 (en) 2004-03-25
KR20110091043A (ko) 2011-08-10
AU2003272460A1 (en) 2004-04-30
US20090292026A1 (en) 2009-11-26
PT1542961E (pt) 2013-11-05
DK1542961T3 (da) 2013-11-04
NZ538741A (en) 2007-01-26
BR0314377A (pt) 2005-07-19
BRPI0314377B1 (pt) 2020-11-24
US7105699B2 (en) 2006-09-12
EP1542961B1 (en) 2013-09-11
ES2431519T3 (es) 2013-11-26
KR101165549B1 (ko) 2012-07-19
CA2498152C (en) 2012-01-10
KR101067045B1 (ko) 2011-09-22
JP4610336B2 (ja) 2011-01-12
MXPA05002700A (es) 2005-09-08
KR20050084552A (ko) 2005-08-26
JP2005539068A (ja) 2005-12-22
EP1542961A1 (en) 2005-06-22
US20060128993A1 (en) 2006-06-15
BRPI0314377B8 (pt) 2021-05-25
US20060216799A1 (en) 2006-09-28

Similar Documents

Publication Publication Date Title
IL167319A (en) Trans 4 - (4,3 - dichlorophenyl) - 1, 2, 3, 4– tetrahydro - 1 - Naphthalamine for use in the treatment of central nervous system disorders
US10702486B2 (en) Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine
CN100584818C (zh) 用反式4-(3,4-二氯苯基)-1,2,3,4-四氢-1-萘胺及其甲酰胺治疗cns病症
HK1143559B (en) Treatment of cns disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed